Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 3/20 | 0.33 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288761 | 0.90 | PDE3B (0.40) | MAPK14MMP13PDE3BPDE3ASLC22A8 | |
| SCHEMBL6292735 | 0.83 | MMP13 (0.35) | MAPK14MMP13PLA2G7PDE3BPDE3A | |
| SCHEMBL6289365 | 0.78 | ADRA1A (0.34) | MAPK14MMP13PLA2G7PDE3BPDE3A | |
| SCHEMBL6289340 | 0.78 | MAPK14 (0.39) | MAPK14S1PR1S1PR3 | |
| SCHEMBL6697068 | 0.75 | MMP13 (0.46) | MMP13SLC22A8GPR18 | |
| SCHEMBL6292115 | 0.74 | MMP13 (0.36) | MAPK14MMP13PLA2G7PDE3BPDE3A | |
| SCHEMBL6289335 | 0.74 | PDE3B (0.38) | MAPK14MMP13PLA2G7PDE3BPDE3A | |
| SCHEMBL6704878 | 0.71 | MMP13 (0.48) | MMP13SLC22A8GPR18 | |
| SCHEMBL6292723 | 0.70 | CYP11B1 (0.32) | MMP13S1PR1S1PR3KCNH2 | |
| SCHEMBL6292839 | 0.69 | MMP13 (0.38) | MMP13PLA2G7PDE3BPDE3ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949651-B2 | Fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | LINCOLN FOODSERVICE PRODUCTS INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2004014375-A2 | FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MAPK14 3042/4885MMP13 9/4885PLA2G7 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.